Learn more Cytokinetics (CYTK) said Thursday that the United Kingdom's Medicines and Healthcare products Regulatory Agency has granted aficamten marketing authorisation across the UK for the treatment ...

Cytokinetics is one of the first drugmakers to benefit from the UK's dual regulatory and reimbursement appraisals, getting a ...

Authorisation from MRHA and Recommendation from NICEThis announcement is intended for business and financial media and investors only SOUTH SAN ...

Study substantially exceeded enrollment target of 500 patientsTopline results anticipated in Q1 2027THE WOODLANDS, Texas, July 27, 2026 (GLOBE ...

Hypertrophic cardiomyopathy is an underdiagnosed genetic disorder, resulting from mutations in sarcomeric proteins. It has a highly variable clinical presentation, with some individuals remaining ...

Background Diabetes mellitus (DM) is a common comorbidity in hypertrophic cardiomyopathy (HCM) and may exacerbate arrhythmic ...

Mavacamten, an investigational allosteric modulator of cardiac myosin, has proved superior to placebo for improving symptoms and reducing or eliminating obstruction of the left ventricle in patients ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Hypertrophic cardiomyopathy (HCM) is a genetic condition characterized by the thickening of the heart muscles. This can happen at any time in life but often begins in adolescence or early adulthood.

Please provide your email address to receive an email when new articles are posted on . Mavacamten (MyoKardia) is a novel, oral, allosteric modulator of cardiac myosin. This therapy was specifically ...